BACKGROUND Unfractionated heparin is often used as adjunctive therapy with fibrinolysis in patients with ST-elevation myocardial infarction. We compared a low-molecular-weight heparin, enoxaparin, with unfractionated heparin for this purpose. METHODS We randomly assigned 20,506 patients with ST-elevation myocardial infarction who were scheduled to undergo fibrinolysis to receive enoxaparin th...

STUDY OBJECTIVES Low-molecular-weight heparins have been compared with unfractionated heparin (UFH) for treatment of deep vein thrombosis (DVT). However, a comparison of their efficacy in the presence or absence of pulmonary embolism (PE) has not been studied. We estimated the efficacy and safety of enoxaparin vs UFH in patients with proximal DVT with/without symptomatic PE using a meta-analysi...

BACKGROUND In the absence of thromboprophylaxis, patients undergoing total hip arthroplasty (THA) are at increased risk for venous thromboembolism (VTE). The objective of this study was to compare the efficacy and safety of edoxaban with enoxaparin for the prevention of VTE after THA in Japan. METHODS This was a phase 3, double-blind, double-dummy, noninferiority study. Patients undergoing el...

OBJECTIVE To detail low molecular mass heparin (enoxaparin) use in the first few months of life. DESIGN Prospective, consecutive cohort of unselected newborn infants. METHODS Newborn infants were divided into groups by gestational age, underlying condition, hepatic and renal function, thrombocytopenia, and prothrombin time (PT/INR). Groups were analysed with respect to many aspects of enoxa...

Dabigatran etexilate was recently approved by the Therapeutic Goods Administration for thromboprophylactic use in adults undergoing elective total hip or knee replacement. Dabigatran etexilate is the prodrug of the active moiety dabigatran, an orally active agent that could replace enoxaparin in some clinical indications. Dabigatran is a direct thrombin inhibitor; it has stable, predictable pha...

We studied the efficacy and safety of an investigational enoxaparin regimen, 1.5 mg/kg once daily, as a bridge to warfarin for the outpatient treatment of acute venous thromboembolism. We undertook a case-control design. We enrolled 40 acute venous thromboembolism cases prospectively and matched them by age, gender, and location of venous thromboembolism to 80 previously treated controls. All c...

Drug utilization evaluation (DUE) is an effective program to identify variability in drug use and to support interventions that will improve patient outcomes. The appropriate use of enoxaparin, a low molecular weight heparin (LMWH), which is widely used as curative or preventive treatment of thromboembolic disorders was assessed in the study. A prospective DUE was carried out at Masih Daneshvar...

Drug utilization evaluation (DUE) is an effective program to identify variability in drug use and to support interventions that will improve patient outcomes. The appropriate use of enoxaparin, a low molecular weight heparin (LMWH), which is widely used as curative or preventive treatment of thromboembolic disorders was assessed in the study. A prospective DUE was carried out at Masih Daneshvar...

BACKGROUND Venous thromboembolic disease in the form of deep venous thrombosis and pulmonary embolism is a major risk after a total hip arthroplasty. Enoxaparin, a low-molecular-weight heparin, has been shown to reduce the prevalence of deep venous thrombosis after total hip arthroplasty. Warfarin, an orally administered anticoagulant, has been used historically to reduce the risk of deep venou...

background: low molecular weight heparin (lmwh) is used for the treatment and prevention of coagulative disorders. few patients receiving therapeutic doses of lmwh develop major hemorrhage. currently there are few reports in the literature on acute overdose on adults.  in this study, clinical profile, treatment and outcome of 21 patients who acutely overdosed enoxaparin are described. methods: ...